Aptuit Holdings, LLC

2017/1/4 10:50


AsiaNet 66964(1653)

【グリニッチ(米コネティカット州)、パルマ(イタリア)2017年1月4日PR Newswire=共同通信JBN】医薬品発見・開発の外部委託研究(CRO)機関の世界大手Aptuit, LLCと、研究を最優先する国際的ヘルスケアグループのChiesi Farmaceutici(Chiesi)は4日、両社が契約を結んだと発表した。契約の下でAptuitは突発性肺線維症(IPF)を治療する革新的な医薬品の供給を目指した総合的な医薬品発見プロジェクトを実施する。

 Logo: http://photos.prnewswire.com/prnh/20150709/234432LOGO






Aptuit Holdings, LLCは、世界的な有力プライベートエクイティ投資家であるWelsh, Carson, Anderson & Stoweと提携している。

さらに詳しい情報はhttp://www.aptuit.com を参照。

▽Chiesi Farmaceuticiについて

Chiesi Farmaceuticiはイタリアのパルマに本社を構え80年以上の経験を持つ研究主体の国際グループである。Chiesiは呼吸器系療法、専門医医療、希少・難治性疾患領域の革新的製薬ソリューションを研究、開発、製品化している。Chiesiは2015年、2014年より9.4%増となる14億ユーロの売上高を記録した。パルマ(イタリア)、パリ(フランス)、ケアリー(米国)、チッペナム(英国)にある同社のR&Dセンターと同社管理課にあるデンマークの企業ZymenexのR&Dチームは、Chiesiの臨床前、臨床、登録プログラムを進める努力を統合している。Chiesi Groupは約4500人を雇用しており、その内560人はR&D活動に専念している。詳しい情報はhttp://www.chiesi.com を参照。


Jim Regan




Valentina Biagini



ソース:Aptuit Holdings, LLC

Aptuit and Chiesi Initiate Integrated Discovery Project to Identify Novel Compounds for the Treatment of Idiopathic Pulmonary Fibrosis


GREENWICH, Connecticut and PARMA, Italy, Jan. 4, 2017 /PRNewswire=KYODO JBN/

    Aptuit, LLC, a premier global drug discovery and development CRO, and

Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare

Group, announced today that they have entered an agreement under which Aptuit

will conduct an integrated Discovery Project aimed at providing innovative

drugs to treat Idiopathic Pulmonary Fibrosis.

     (Logo: http://photos.prnewswire.com/prnh/20150709/234432LOGO )

    Both parties will contribute scientifically, with Aptuit providing

integrated early Discovery capabilities, including Medicinal Chemistry and

Pharmacology, as well as Drug Metabolism and Pharmacokinetics, in order to

identify promising compounds for further pre-clinical development.  

    Dr. Jonathan Goldman, Chief Executive Officer, Aptuit, stated, "This

project builds upon the existing relationship between Chiesi and Aptuit in the

field of Respiratory Drug Discovery. We are delighted to be working with Chiesi

to identify early stage compounds that we hope will ultimately progress into

innovative treatments for patients with this debilitating disease".  

    Dr. Mark Parry Billings, Corporate Drug Development Head, Chiesi

Farmaceutici, commented, "We are very pleased to announce the partnership with

Aptuit.  We share a common culture of scientific excellence and commitment to

quality research and development. This alliance will allow our Project to

progress effectively to the identification of lead compounds with a novel

mechanism of action, leveraging our joint expertise in Respiratory drug


    About Aptuit

    Aptuit provides the most complete set of integrated early discovery to

mid-phase drug development services in the pharmaceutical industry including

Drug Design & Discovery, API Development and Manufacture, Solid State

Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated

drug discovery & development services are available from our facilities in the

UK, Italy, and Switzerland.

    Aptuit Holdings, LLC is partnered with Welsh, Carson, and Anderson & Stowe,

one of the world's leading private equity investors.

    For more information: http://www.aptuit.com

    About Chiesi Farmaceutici

    Chiesi Farmaceutici is a research-focused international group, with more

than 80 years of experience headquartered in Parma (Italy). Chiesi researches,

develops and commercializes innovative pharmaceutical solutions in the

respiratory therapeutics, specialist medicine and rare diseases areas. In 2015,

Chiesi achieved sales of over 1.4 billion Euros, constituting a 9.4 % growth

over 2014. Its R&D centers in Parma (Italy), Paris (France), Cary (USA),

Chippenham (UK) and the R&D team of the controlled Danish company Zymenex,

integrate their efforts to advance Chiesi's pre-clinical, clinical and

registration programs. The Chiesi Group employs approximately 4500 people, 560

of which are dedicated to R&D activities.

For more information: http://www.chiesi.com

    For more information about Aptuit

    Jim Regan



    For more information about Chiesi

    Valentina Biagini



SOURCE: Aptuit Holdings, LLC